Stallergenes Greer announces U.S. FDA approval of paediatric indication extension for Oralair sublingual immunotherapy tablet for the treatment of grass pollen allergy

14 November 2018 - Stallergenes Greer today announced that it has received approval from the U.S. FDA for the extension of ...

Read more →

Disclosing prescription-drug prices in advertisements — legal and public health issues

14 November 2018 - On October 15, 2018, the CMS proposed a rule requiring television advertisements for prescription drugs and ...

Read more →

Pfizer launches epoetin alfa biosimilar, Retacrit, at 33.5% discount to reference Epogen

14 November 2018 - Pfizer announced today that it has launched its epoetin alfa biosimilar, Retacrit, at a substantial discount to ...

Read more →

U.S. FDA accepts for filing Shire’s supplemental new drug application for Gattex (teduglutide [rDNA origin]) for children with short bowel syndrome

13 November 2018 - Seeking approval for the potential use of Gattex to paediatric patients builds on Shire’s decade-long commitment ...

Read more →

Retrophin announces U.S. FDA acceptance of NDA filing for the new formulation of Thiola (tiopronin) in the treatment of cystinuria

12 November 2018 - PDUFA date set for 30 June 2019. ...

Read more →

Pain Therapeutics appeals FDA decision on Remoxy

12 November 2018 - Pain Therapeutics today announced that it has petitioned the FDA regarding a complete response letter for ...

Read more →

Palvella Therapeutics announces FDA fast track designation for PTX-022 for treatment of pachyonychia congenita

12 November 2018 - Palvella Therapeutics today announced that the U.S. FDA has granted fast track designation for its lead product ...

Read more →

Lilly submits new drug application to the FDA for lasmiditan for acute treatment of migraine, receives breakthrough therapy designation for Emgality (galcanezumab-gnlm) for prevention of episodic cluster headache

14 November 2018 - Lilly also plans to submit a supplemental biologics license application to the FDA for Emgality for the ...

Read more →

FDA takes steps to allow greater flexibility for clinical investigators about informed consent in minimal risk situations

13 November 2018 - Today, the U.S. FDA is proposing to amend its regulations to implement a provision of the ...

Read more →

FDA grants priority review to Roche’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer

13 November 2018 - If approved, this Tecentriq (atezolizumab) combination would be the first cancer immunotherapy regimen for the treatment ...

Read more →

US FDA accepts regulatory submission for Lynparza maintenance therapy in newly-diagnosed, BRCA mutated advanced ovarian cancer and grants priority review

12 November 2018 - First US regulatory submission acceptance for a PARP inhibitor as a first-line maintenance treatment for advanced ...

Read more →

Drug prices on ads: as ‘relevant’ as percent daily value on food labels

9 November 2018 - President Trump announced late last month that his administration will push back on high drug costs ...

Read more →

Karyopharm’s selinexor receives fast track designation from FDA for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma

7 November 2018 - Karyopharm Therapeutics today announced that the U.S. FDA has granted fast track designation to selinexor, the Company’s ...

Read more →

Theravance Biopharma and Mylan receive FDA approval for Yuperli (revefenacin) in adults with chronic obstructive pulmonary disease

9 November 2018 - Yuperli (revefenacin) is the first and only once-daily, nebulised bronchodilator approved for the treatment of COPD in ...

Read more →

FDA highlights record-breaking number of generic drug approvals in October

9 November 2018 - Today, the U.S. FDA is providing a summary of the generic drug approval actions for the ...

Read more →